tetrapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
The four residues give epitalon a molecular formula of C14H22N4O9 and a molecular weight near 390.35 daltons. The presence of two acidic residues, glutamate and aspartate, makes the free peptide strongly acidic, while the alanine and glycine ends provide neutral, nonpolar character. This combination produces a molecule with substantial water solubility. Because there are no cysteine, methionine, or tryptophan residues, the peptide lacks the most common oxidation-sensitive side chains, which simplifies handling compared with many longer peptides.
The proposed relationship between epitalon and pineal function is a central part of its background. Khavinson's group reported that short peptides corresponding to regions of larger pineal proteins could influence gene expression in cells. Epitalon was framed as a synthetic analogue of an active fragment rather than a direct isolation product. Whether the tetrapeptide reproduces the effects of the parent extract is an open question, because comparative studies are limited and the parent extract itself is not a single defined substance.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
| Property | Value | Notes |
|---|---|---|
| Amino acid sequence | Ala-Glu-Asp-Gly | Tetrapeptide, often abbreviated AEDG |
| Molecular formula | C14H22N4O9 | Free peptide, unmodified termini |
| Molecular weight | ~390.35 Da | Calculated for the free acid form |
| Appearance | White to off-white powder | Typical lyophilized product form |
| Solubility class | Freely soluble in water | Two acidic residues dominate ionic character |
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
=== Muscle mass === Researchers are still debating whether the more noticeable muscles are larger in size as well. It should be clarified, though, that muscle mass is not the same as muscle strength. Some say that human growth hormone will build muscle mass through raised insulin-like growth factors levels leading to heightened protein synthesis without any side effects while other researchers argue that there have been no such findings on young healthy adults. The second argument is more supported by research discoveries that HGH affects muscle protein synthesis no differently than a placebo does.
The two substrates of this enzyme are 2-dehydro-D-gluconic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are 2,5-didehydro-D-gluconic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 2-dehydro-D-gluconate:NADP+ 2-oxidoreductase. Other names in common use include 2,5-diketo-D-gluconate reductase, and YqhE reductase.
== History == Hyaluronic acid was first obtained by Karl Meyer and John Palmer in 1934 from the vitreous body in a cow's eye. The first hyaluronan biomedical product, Healon, was developed in the 1970s and 1980s by Pharmacia, and approved for use in eye surgery (i.e., corneal transplantation, cataract surgery, glaucoma surgery, and surgery to repair retinal detachment). Other biomedical companies also produce brands of hyaluronan for ophthalmic surgery. Native hyaluronic acid has a relatively short half-life (shown in rabbits) so various manufacturing techniques have been deployed to extend the length of the chain and stabilise the molecule for its use in medical applications. The introduction of protein-based cross-links, the introduction of free-radical scavenging molecules such as sorbitol, and minimal stabilisation of the HA chains through chemical agents such as NASHA (non-animal stabilised hyaluronic acid) are all techniques that have been used to preserve its shelf life. In the late 1970s, intraocular lens implantation was often followed by severe corneal edema, due to endothelial cell damage during the surgery. It was evident that a viscous, clear, physiologic lubricant to prevent such scraping of the endothelial cells was needed.
Sources: en.wikipedia.org
He arranged for the bosses of the leading banks and building societies to tour the area in a coach (they were reluctant until Heseltine's PPS Tim Sainsbury persuaded Robin Leigh-Pemberton of NatWest to come), and asked them to each second a bright young manager to the DOE for a year. Heseltine circulated a 21-page minute to Cabinet on his return, entitled It Took a Riot. He proposed a regional office and a review of the status of the Metropolitan Counties, as well as greater government emphasis on Merseyside in future. He had prepared the ground with a small dinner for Whitehall mandarins including Robert Armstrong (Cabinet Secretary) and Ian Bancroft (Head of the Civil Service). However, Thatcher was not impressed, although she agreed to his appointment as Minister for Merseyside for twelve months. Neither was Keith Joseph (Secretary of State for Industry) nor Howe (Chancellor of the Exchequer), who favoured enterprise zones where businesses would be given favourable tax treatment. Shortly after his appointment as Minister for Merseyside, Heseltine gave his annual party conference speech, in which he condemned talk of repatriation and called for more public spending on inner cities. Although he felt he had taken a risk – the speech was in marked contrast to Norman Tebbit's "On Your Bike" speech a few hours later – he received his usual standing ovation and later recorded that it was the one of his speeches of which he was most proud.
Yawn and swallow during ascent and descent Use the Valsalva maneuver during ascent and descent Avoid sleeping during takeoffs and landings Use an over the counter nasal spray Using filtered earplugs which slowly equalize the pressure against the eardrum during ascents and descents Outside of a pressurized cabin environment at very high altitudes, a pressure suit is the usual protective measure and is the definitive protection in decompression and exposure to vacuum, but they are expensive, heavy, bulky, restrict mobility, cause thermal regulatory problems, and reduce comfort. To prevent injury from unavoidable pressure changes, similar equalization techniques and relatively slow pressure changes are required, which in turn require patent Eustachian tubes and sinuses.
=== Laboratory evaluation === Polycythemia is often initially identified on a complete blood count (CBC). The CBC is often repeated to evaluate for persistent polycythemia. If an etiology of polycythemia is unclear from history or physical, additional laboratory evaluation might include:
Sources: en.wikipedia.org
An agent harness, or agent scaffold, is the software layer surrounding a large language model that enables it to function as an AI agent. It commonly manages prompts, context, tool use, memory, execution state, operational constraints, sandboxes, permissions, and the processing of results. The harness connects the model to internal and external computer hardware, software, data files, databases, web browsers, command-line interfaces, and application programming interfaces, while controlling how the agent accesses and uses these resources to complete multi-step tasks.
The cover artwork for the album was designed by American artist Kaws, featuring his Companion character being assembled, or "sorted out", by two hands. Kaws has been a known collaborator with Clipse, having also designed the cover art for their 2009 album Til the Casket Drops. American artist Josh Sperling described his two alternate album covers as "The Cross and the Anchor. The Cross to represent sin, death and faith. The Anchor to represent strength and stability in unknown waters. Two symbols for Two brothers."
Source 2 has also been used for Valve's Artifact and Dota Underlords, with the engine later being supported on Android and iOS for the latter. The engine also supports the creation of games in virtual reality, being used in SteamVR Home, the Robot Repair tech demo within The Lab, and Half-Life: Alyx. Source 2 tools made specifically for creating content for Half-Life: Alyx were released in May 2020.
Sources: en.wikipedia.org
Epitalon is a synthetic tetrapeptide composed of four amino acids: alanine, glutamate, aspartate, and glycine. It is written as Ala-Glu-Asp-Gly. The free peptide has a molecular weight of about 390 daltons and is normally supplied as a lyophilized powder.
No. Epitalon is chemically synthesized, not extracted. It was designed as a short synthetic fragment conceptually related to larger pineal peptides studied in the same research tradition, particularly the extract known as epithalamin. The two are distinct materials with different compositions.
The term bioregulator is used in this research tradition for short peptides proposed to influence gene expression or cell function. Epitalon is grouped with other synthetic short peptides under this label. The term reflects a proposed mechanism rather than an established drug classification.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.